Published in Hepatology on August 24, 2011
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis | NCT00590161
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol (2013) 1.90
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res (2012) 1.51
Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci (2013) 1.25
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol (2013) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology (2013) 1.10
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 1.08
Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res (2013) 1.03
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci (2014) 1.00
Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol (2016) 0.97
Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol (2015) 0.95
Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci (2014) 0.92
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc (2015) 0.90
Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Lipids Health Dis (2012) 0.90
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.90
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
Non-alcoholic fatty liver disease in 2015. World J Hepatol (2015) 0.88
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.88
Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol (2014) 0.87
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol (2014) 0.87
Alcoholic Liver Disease: Update on the Role of Dietary Fat. Biomolecules (2016) 0.86
Oxidized fatty acids: A potential pathogenic link between fatty liver and type 2 diabetes in obese adolescents? Antioxid Redox Signal (2013) 0.84
Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol (2015) 0.84
Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y) (2014) 0.84
Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol (2015) 0.83
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia (2016) 0.82
Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2012) 0.82
Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood) (2015) 0.81
Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J (2012) 0.81
Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Ann Gastroenterol (2012) 0.81
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol (2012) 0.81
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol (2016) 0.81
Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci (2016) 0.81
Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol (2014) 0.80
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol (2016) 0.78
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol (2016) 0.78
Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clin Lipidol (2013) 0.78
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci (2016) 0.77
Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep (2014) 0.77
Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetol Metab Syndr (2015) 0.77
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators Inflamm (2016) 0.77
Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. World J Hepatol (2015) 0.77
Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. J Pathol (2016) 0.77
(-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus (2013) 0.76
Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract (2015) 0.76
Non-alcoholic fatty liver disease. BMC Med (2017) 0.75
The Role of Butylidenephthalide in Targeting the Microenvironment Which Contributes to Liver Fibrosis Amelioration. Front Pharmacol (2016) 0.75
Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON). J Pediatr (2016) 0.75
Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis (2015) 0.75
Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open (2017) 0.75
Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi J Gastroenterol (2016) 0.75
Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med (2017) 0.75
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore) (2016) 0.75
Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. Hepat Mon (2015) 0.75
Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology (2011) 0.75
Preventive Effects of Pentoxifylline on the Development of Colonic Premalignant Lesions in Obese and Diabetic Mice. Int J Mol Sci (2017) 0.75
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clin Diabetes Endocrinol (2016) 0.75
Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. Exp Ther Med (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Quantitative estimation of insulin sensitivity. Am J Physiol (1979) 7.37
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther (2003) 4.34
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med (2000) 3.47
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest (1987) 2.81
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 2.54
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 2.19
Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab (1990) 1.71
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Is bacterial ash the flash that ignites NASH? Gut (2001) 1.36
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.33
Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol (2008) 1.33
Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1998) 1.32
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut (2002) 1.29
Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol (2004) 1.19
Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol (1995) 1.11
Measurement of cell death. Methods Cell Biol (1998) 1.10
Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol (1990) 0.95
Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol (1995) 0.94
Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol Res (2002) 0.91
The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue. Arzneimittelforschung (1982) 0.90
Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology (1997) 0.85
Effect of pentoxifylline on the degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor-beta 1. Br J Pharmacol (1997) 0.85
Effect of pentoxifylline and somatostatin on tumour necrosis factor production by human pulmonary macrophages. Circ Shock (1994) 0.84
In vivo effects of pentoxifylline on enzyme and non-enzyme antioxidant levels in rat liver after carrageenan-induced paw inflammation. Cell Biochem Funct (2010) 0.83
Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation. Hepatology (1995) 0.81
Effect of pentoxifylline on hepatic injury caused in the rat by the administration of carbon tetrachloride or acetaminophen. Pharmacol Rep (2005) 0.79
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Alcoholic liver disease. Hepatology (2010) 5.04
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology (2010) 4.83
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology (2010) 4.11
Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol (2008) 4.01
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Bariatric surgery improves the metabolic profile of morbidly obese patients with type 1 diabetes. Diabetes Care (2014) 3.13
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int (2011) 2.85
Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2011) 2.46
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol (2008) 2.45
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes (2008) 2.42
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology (2014) 2.22
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol (1985) (2005) 2.18
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem (2009) 2.13
Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem (2009) 2.11
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm Bowel Dis (2014) 2.05
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis (2008) 2.04
Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. Gastroenterology (2009) 2.02
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Patients do not recall important details about polyps, required for colorectal cancer prevention. Clin Gastroenterol Hepatol (2012) 2.01
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Adenomas are detected more often in morning than in afternoon colonoscopy. Am J Gastroenterol (2009) 1.97
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg (2013) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol (2009) 1.88
Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem (2007) 1.85
Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr (2005) 1.84
Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care (2013) 1.83
Antegrade is more effective than retrograde enteroscopy for evaluation and management of suspected small-bowel disease. Clin Gastroenterol Hepatol (2012) 1.82
Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med (2016) 1.82
Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol (1985) (2008) 1.80
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.78
Propofol versus traditional sedative agents for gastrointestinal endoscopy: a meta-analysis. Clin Gastroenterol Hepatol (2005) 1.77
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol (2013) 1.75
Utilization of and adherence to the gastroenterology core curriculum on hepatology training during a gastrointestinal fellowship. Clin Gastroenterol Hepatol (2008) 1.72
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr (2003) 1.70
Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care (2007) 1.70
Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain (2013) 1.69
Adenoma and early stage adenocarcinoma of the appendix: diagnosis by colonoscopy. Gastrointest Endosc (2004) 1.65
Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol (2011) 1.65
Individuals with sessile serrated polyps express an aggressive colorectal phenotype. Dis Colon Rectum (2011) 1.64
Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol (2013) 1.63
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl (2008) 1.61
Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. Am J Gastroenterol (2005) 1.61
A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc (2008) 1.60
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr (2011) 1.59
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res (2010) 1.53
Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 1.52
Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets (2013) 1.52
Clinical utility of wireless motility capsule in patients with suspected multiregional gastrointestinal dysmotility. Dig Dis Sci (2014) 1.52
Findings on endoscopic retrograde cholangiopancreatography and pancreatic function test in suspected chronic pancreatitis and negative cross-sectional imaging. Clin Gastroenterol Hepatol (2008) 1.51
Safety of cardiac surgery for patients with cirrhosis and Child-Pugh scores less than 8. Clin Gastroenterol Hepatol (2011) 1.48
Adding triamcinolone to endoscopic ultrasound-guided celiac plexus blockade does not reduce pain in patients with chronic pancreatitis. Clin Gastroenterol Hepatol (2011) 1.48
Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care (2010) 1.46
An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc (2009) 1.44
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol (2008) 1.36
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 1.33
Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol (2008) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32